Shire announced the launch of Natpara (parathyroid hormone) for injection indicated as adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism Shire announced the ...

PHOENIX — Researchers have shown that parathyroid hormone stimulated fracture healing in an animal model and that it may be mediated by the Wnt signaling pathway. Sanjeev Kakar, MD, of Boston, ...

Takeda is working closely with the US Food and Drug Administration (US FDA) to resolve the issue and resume supply as soon as possible With patient safety as the company's main priority, Takeda is ...

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that Natpara® (parathyroid hormone) for injection is now available in the United States. The U.S. Food and Drug Administration (FDA) approved Natpara ...

Please provide your email address to receive an email when new articles are posted on . Takeda recently announced it is issuing a U.S. recall for all doses of its parathyroid hormone injection due to ...

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that Natpara® (parathyroid hormone) for injection is now available in the United States. The U.S. Food and Drug Administration (FDA) approved Natpara ...

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the U.S.

Patients are advised to immediately consult their healthcare providers to help ensure safe discontinuation of NATPARA treatment Takeda is working closely with the US Food and Drug Administration (US ...

NATPARA, a recombinant human protein with the full length 84-amino-acid sequence of endogenous parathyroid hormone (PTH), is currently approved in the US as the only adjunctive treatment for adult ...

Takeda is working closely with the US Food and Drug Administration (US FDA) to resolve the issue and resume supply as soon as possible OSAKA, Japan, Sept. 5, 2019 /CNW/ -- Takeda Pharmaceutical ...

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the company is issuing a US recall for all doses of NATPARA® (parathyroid hormone) for Injection (25 mcg, 50 ...

Takeda is working closely with the US Food and Drug Administration (US FDA) to resolve the issue and resume supply as soon as possible OSAKA, Japan, Sept. 5, 2019 /CNW/ -- Takeda Pharmaceutical ...